Status:
WITHDRAWN
Study of FTY720 in Patients With Uveitis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis
Eligibility Criteria
Inclusion
- Acute noninfectious posterior, intermediate, or pan uveitis
- Vitreous haze score of 1+ or more in the study eye at screening and baseline visits
Exclusion
- Vaso-occlusive vasculitis involving the retinal macula
- Behçet's uveitis
- Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)
- Other protocol defined inclusions and/or exclusions may apply.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01791192
Start Date
November 1 2013
End Date
October 1 2014
Last Update
April 20 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.